Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Merck

Trump’s vaccine overhaul could bring more shots, higher costs for US families

President Donald Trump's vaccine plan faces significant financial and logistical hurdles. Drugmakers must develop new manufacturing processes and conduct extensive clinical studies. Separating vaccines could lead to more appointments and increased costs for families. Public health experts question the scientific basis for the proposed changes. States retain authority to mandate…

The Economic Times

Trump's vaccine plan would require millions of individual shots last used decades ago

The biggest obstacles to President Donald Trump’s order on vaccines may be the logistical challenges it poses for U.S. parents, health providers and drugmakers

The Independent UK

Executive order on vaccines bypasses an evidence-based process that has kept kids safe

President Donald Trump signed an executive order on Aug. 10, 2026, calling for the combined measles, mumps and rubella vaccine to be given as three separate shots at three separate appointments. The combined MMR vaccine is currently given at 12 to 15 months of age and again between ages 4…

The Conversation

From analysis to the latest developments in health,
read the most diverse news in one place.

Weekly HIV Pill Held Viral Suppression as Well as Daily Therapy in Phase 3 Trial

A once-weekly HIV pill matched daily therapy for viral suppression in a phase 3 trial. It is not approved yet. Here is what the data show.

Medical Daily

Merck & Co’s Stock: Analyst Estimates & Ratings

Merck has outperformed the broader market over the past year, and analysts remain optimistic about the stock.

Barchart

Once-Weekly HIV Pill Held Viral Suppression as Well as Daily Treatment in Two Phase 3 Trials

Two phase 3 trials found that a weekly islatravir and lenacapavir tablet matched daily HIV therapy at 48 weeks. Here is what the data show.

Medical Daily

Africa CDC Moves to Test Merck's Licensed Ebola Vaccine Against Bundibugyo as Congo Outbreak Becomes Country's Largest

Africa CDC plans to ask WHO advisers to allow testing of Ervebo against Bundibugyo Ebola. No trial is approved, and no protection is proven.

Medical Daily

Read news from The Economist, FT, and more,
with one subscription

Earnings, PMI and Other Key Things to Watch this Week

Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide a critical assessment of economic health and corporate fundamentals amid persistent uncertainty about technology sector valuations and AI infrastructure spending.

Barchart

Stockpiled Ebola Vaccines Produced an Antibody Response Against the Strain Driving the Congo Outbreak

New NEJM data show licensed Zaire Ebola vaccines produce some antibody response against Bundibugyo, the strain behind the record Congo outbreak.

Medical Daily

FDA Approves the First Oral PCSK9 Inhibitor, Ending the Injection-Only Era for a Major Cholesterol Drug Class

FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor for adults with high LDL cholesterol. What it changes and what remains unknown.

Medical Daily

FDA Expands Keytruda Approval to All Bladder Cancer Patients Before Surgery, Not Just Those Avoiding Chemo

The FDA expanded Keytruda plus Padcev to all muscle-invasive bladder cancer patients on July 10, 2026. Here is who now qualifies and what the KEYNOTE-B15 trial showed.

Medical Daily

Behind the patient campaigns, the pharma giants profiting from public pressure

Comment: Auckland’s Forbidden Pharmacy highlights 200 unfunded drugs as patient advocates push politicians for more money.Listening to them, you’d think NZ was a cheapskate in funding healthcare – but in fact, it’s in the top half of the OECD. Jonathan Milne reports.

Newsroom.co.nz

FDA Approves Lipfendra, the First Oral PCSK9 Inhibitor: A Once-Daily Pill That Cuts LDL Cholesterol as Well as Injectables

FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, on July 16, 2026. The once-daily pill cut LDL by up to 59% in trials. Here's who it's for.

Medical Daily

Nasdaq Sinks as Chip Stocks Drop Again: Stock Market Today

While Taiwan Semi's post-earnings drop pressured chipmakers, healthcare names outperformed thanks to Merck's FDA win and Eli Lilly's big buy.

Kiplinger

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Merck gets US FDA nod for first-in-its-class oral cholesterol drug

The U.S. FDA has approved Merck's new cholesterol-lowering pill, Lipfendra. This oral medication works by blocking the PCSK9 protein, which helps lower bad cholesterol. Lipfendra offers an alternative for patients who dislike injectable treatments for heart disease. The drug is priced at $10.50 daily and will be available soon. Merck…

The Independent UK

FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients

The Food and Drug Administration has approved a first-of-its-kind pill that can drastically reduce cholesterol

The Guardian - US

Drugmaker Merck announces approval of new cholesterol-fighting drug

Lipfendra can be taken in conjunction with or an alternative to statins, the most prescribed medication in the US

International Business Times

FDA Clears First Of Its Kind Cholesterol Medication: Lipfendra Makes History

The U.S. Food and Drug Administration has approved Merck's Lipfendra (enlicitide), making it the first oral PCSK9 inhibitor available in the United States and offering millions of patients with high cholesterol a new alternative to injectable therapies.

Get all your
news in one place.

100's of premium titles.
One news app.

Bored Panda

Hair Transplants Carry A Life-Changing Risk That Nobody Is Talking About

For many people, a hair transplant feels like the end of a long battle with hair loss. But the medication often recommended afterward has become the center of an increasingly bitter medical debate. This investigation examines what clinics tell patients, what regulators now warn, and why some experts believe informed…

Barchart

This Blue-Chip Dividend Stock Is Outperforming the S&P 500 in 2026

Merck & Co. has outperformed the S&P 500 in 2026, rising 19% year-to-date while offering a 2.61% dividend yield supported by 15 consecutive years of dividend increases.

Kiplinger

Pet Stocks Have Slipped Since COVID. Is This an Investing Opportunity?

Americans still love their pets, and ownership keeps rising. So what happened to pet stocks?

We Got This Covered

New Jersey woman warns that a $1.8 billion AI plant is being built next to Manhattan Bagel. Then asked who’s actually benefiting

250 megawatts and a lot of questions.

Medical Daily

A New Vaccine Option Is Now Available for Kids with Diabetes, Heart Disease, or Other Chronic Conditions

FDA approved Capvaxive for kids 2-17 with chronic conditions like diabetes and heart disease, June 18, 2026. Here's what families managing pediatric chronic illness need to know.

Barchart

The $11 Billion Reason TECH Stock Is Up Today

Bio-Techne stock rallies as Merck announces an agreement to acquire it for $73 per share. But is there any further upside left in TECH shares?

Barchart

How to Buy Merck Stock for a 10% Discount or Achieve an 11% Annual Return

On Monday, with Merck trading at $119.60, the August put option with a strike price of $110 was trading around $2.03. Traders selling this put would receive $230 in option premium. In return for receiving this premium, they have an obligation to buy 100 shares of MRK for $110.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.